
World Ovarian Cancer Coalition Launches Global Expert Advisory Group on Ovarian Cancer
TORONTO--(BUSINESS WIRE)--On World Ovarian Cancer Day (#WOCD2025), the World Ovarian Cancer Coalition (the Coalition) announces the formation of the Global Expert Advisory Group on Ovarian Cancer, a new initiative to elevate ovarian cancer as a global health priority.
On World Ovarian Cancer Day (#WOCD2025), the World Ovarian Cancer Coalition announces the formation of the Global Expert Advisory Group on Ovarian Cancer, a new initiative to elevate ovarian cancer as a global health priority.
Share
Ovarian cancer is the most lethal of female cancers. With no reliable screening test, low awareness and significant diagnostic barriers, millions of lives are at stake - particularly in low- and middle-income countries where the burden is disproportionately high. Without urgent action, the world could lose eight million women to ovarian cancer by 2050.
The newly formed Global Expert Advisory Group on Ovarian Cancer brings together patient advocates, leading clinicians and policy makers from 13 nations across six continents. The group's mission is to develop a comprehensive framework for a global ovarian cancer strategy that will have an impact at country level to ensure that everyone living with, or at risk of, ovarian cancer has the best chance of survival and the best quality of life possible, no matter where they live. The group has identified three critical areas of focus:
Building Community and Policymaker Awareness
Optimising Routes to Diagnosis
Access to Services and Treatment for Hereditary Ovarian Cancer
The Group is chaired by World Ovarian Cancer Coalition Board Member (and past Chair) Annwen Jones OBE and Assoc. Professor Tracey Adams, a Gynaecological Oncologist at Groote Schuur Hospital University of Cape Town, South Africa. 'This is a global challenge that demands a global response,' said the Co-Chairs. 'Alongside the key areas of focus, we plan to set a target for a reduction in global ovarian cancer mortality in a similar vein to the global breast cancer initiative.'
The announcement builds on findings from the Coalition's recent studies: the Socioeconomic Burden of Ovarian Cancer in 11 Countries and the groundbreaking Every Woman Study™: Low- and Middle-Income Edition. These studies revealed:
Exceptionally low awareness of ovarian cancer among women globally
Lack of knowledge about genetic risk including the BRCA1 and BRCA2 mutations
The huge socioeconomic burden of the disease on families, healthcare systems and national economies
The Group's members are:
Dr. Carlos Andrade, Assistant at Gynecologic Oncology Department, Barretos Cancer Hospítal (Brazil)
Dr. Garth Funston, Lecturer, Wolfson Institute of Population Health (UK)
Nimkee Gupta, Patient advocate (India and Luxembourg)
Jennifer Hollington, Retired assistant deputy minister in the Government of Canada, Patient advocate (Canada)
Dilyara Kaidarova, MD, PhD, Prof., First Vice-Rector, Asfendiyarov Kazakh National Medical University (Kazakhstan)
Bar Levy, CEO, HaBait Shel Bar- Israel's Women's Cancer Association, Patient Advocate (Israel)
Prof. Ranjit Manchanda, Professor of Gynaecological Oncology, Wolfson Institute of Population Health (UK)
Prof. Ursula Matulonis, Chief, Division of Gynecologic Oncology, Dana-Farber Cancer Institute (US)
Dr. Asima Mukhopadhyay, Founder and Director, KolGOTrg, Gynaecological Oncologist/Surgeon, James Cook University Hospital and Newcastle University (India and UK)
Dr. Aisha Mustapha, Consultant Obstetrician Gynaecologist, Ahmadu Bello University (Nigeria)
Dr. Florencia Noll, Head of Unit, Sanatario Allende Cerro (Argentina)
Prof. Amit Oza, Head, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre (Canada)
Sarah Powell, CEO, Inherited Cancers Australia (Australia)
Prof. Basel Refky, Oncology Center, Mansoura University (Egypt)
Dr. Ritu Salani, Professor, Department of Obstetrics and Gynecology, David Geffen School of Medicine, UCLA (US)
Sbba Siddique, Patient advocate (UK)
Prof. Sudha Sundar, Gynaecological oncology, University of Birmingham (UK)
Carolyn Taylor, Founder & Executive Director, Global Focus on Cancer (US)
Dr. Julie Torode, Director Strategic Partnerships, Patient and Community Engagement, Institute of Cancer Policy, Kings College of London, and Board Member, World Ovarian Cancer Coalition (Switzerland and UK)
About the World Ovarian Cancer Coalition
The World Ovarian Cancer Coalition, the only global not-for-profit organization focused solely on ovarian cancer, was established in 2016 and comprises over 200 patient advocacy group members in 37 countries. We work globally to ensure that everyone living with, or at risk of, ovarian cancer has the best chance of survival and the best quality of life, no matter where they live. To learn more, visit our website and follow us on LinkedIn, Facebook, Instagram, X and YouTube.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 hours ago
- Yahoo
Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination
EWING, N.J., June 6, 2025 /PRNewswire/ -- Church & Dwight Co., Inc. is voluntarily recalling all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. The products are being recalled due to potential microbial contamination identified as fungi in cotton swab components. Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions. To date, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico. Recalled Product Information Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. What Consumers Should Do Consumers who have purchased any of the recalled products should stop using the product immediately. Please visit or call its Consumer Relations team at (800) 981-4710 for a full refund. Any additional questions can also be directed to its Consumer Relations team Monday through Friday, 9am – 5pm ET. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall. About Church & Dwight Co., Inc. Church & Dwight Co., Inc. is a leading manufacturer of consumer household and personal care products. For more information, visit Media Contact:Keith View original content to download multimedia: SOURCE Church & Dwight Co. Sign in to access your portfolio
Yahoo
20 hours ago
- Yahoo
Church & Dwight Co., Inc. Issues Voluntary Nationwide Recall of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs Due to Microbial Contamination
EWING, N.J., June 6, 2025 /PRNewswire/ -- Church & Dwight Co., Inc. is voluntarily recalling all lots within expiry of Zicam® Cold Remedy Nasal Swabs, Zicam® Nasal AllClear Swabs, and Orajel™ Baby Teething Swabs to the consumer level. The products are being recalled due to potential microbial contamination identified as fungi in cotton swab components. Swabs found to contain microbial contamination can potentially present a significant risk to the health and safety of consumers including serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injuries. The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions. To date, no serious adverse events associated with the affected product have been reported. The recalled products were distributed nationwide in the United States and in Puerto Rico. Recalled Product Information Zicam® Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam® Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product (discontinued in December 2024). Orajel™ Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. What Consumers Should Do Consumers who have purchased any of the recalled products should stop using the product immediately. Please visit or call its Consumer Relations team at (800) 981-4710 for a full refund. Any additional questions can also be directed to its Consumer Relations team Monday through Friday, 9am – 5pm ET. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax. Complete and submit the report Online: Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration. This recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall. About Church & Dwight Co., Inc. Church & Dwight Co., Inc. is a leading manufacturer of consumer household and personal care products. For more information, visit Media Contact:Keith View original content to download multimedia: SOURCE Church & Dwight Co. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Enovis to Participate in Upcoming Investor Conferences
Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Goldman Sachs 46th Annual Global Healthcare Conference: Ben Berry, Chief Financial Officer, will participate in a fireside chat on Tuesday, June 10th at 2:00 p.m. Eastern Time. Citizens Medical Devices and Healthcare Services Forum: Ben Berry, Chief Financial Officer, will participate in investor meetings on Tuesday, June 17th. A link to the live audio webcasts, if available, as well as a replay of these events, will be available on the Company's website under the Investors tab at Events and Presentations. ABOUT ENOVIS Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company's extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company's shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit Contact: Kyle RoseVice President, Investor RelationsEnovis Corporationinvestorrelations@